Creating “future proof” antibodies vs. virus variants like Omicron with Ian Chan, co-founder of Abpro
From Lab to Launch by Qualio
English - January 21, 2022 21:00 - 15 minutes - 11 MBLife Sciences Science Business Entrepreneurship life sciences medical device biotech quality management entrepreneurship Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Today's guest is Ian Chan the co-founder and executive chairman of Abpro. Abpro is improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Ian explains how their technology is "future proofing" antibodies.
Recently, Abpro announced its ABP 310 COVID antibody retains neutralization activity against the SARS-CoV-2 Omicron variant, which is exciting.
You’ll hear the full story coming up but first some quick takeaways you’ll get from today’s conversation:
How Abpro is cutting the time to generate antibodies for testing from 1 year to 2 months. What all founders should focus on to facilitate fundraising - what Ian calls “first-class science”Unique challenges a company faces when it’s in high-growth mode and how to prepare.More about Ian he co-founded Abpro with his brother, Dr. Eugene Chan, who is the CEO. Not everyone goes into business with family but they’ve done it successfully a few times actually. Ian received an AB from Brown University and MBA from Harvard University.
Show notes:
https://abpro.com/
Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant
Qualio
Apply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez
Qualio website:
https://www.qualio.com/
Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8
Music by keldez